Figure 1.
Clinical, pathologic, and molecular characteristics of MLN-Eo with ETV6-FLT3 fusion in the study patient. (A) Skin rash at presentation. (B, top) Representative histologic smears from bone marrow at diagnosis, following sorafenib therapy, and in full MRD-negative complete response after gilteritinib. (B, bottom) Skin biopsy samples showed involvement by same infiltrative process affecting bone marrow. (C) Partial karyogram showing t(12;13)(p13;q12) and FISH confirming ETV6 rearrangement in multiple sorted abnormal cell populations. (D) Schematic illustration of fusion gene product and transcript sequence of the ETV6 (NM_001987)-FLT3 (NM_004119) in-frame fusion product. Exons 1-6 of ETV6 are fused to exons 14-24 of FLT3, which include the kinase domain. Red and blue rectangles represent bidirectional RNA-sequencing reads supporting the fusion breakpoint. H&E, hematoxylin and eosin; HLH, helix-loop-helix domain; KID, kinase insert domain.

Clinical, pathologic, and molecular characteristics of MLN-Eo with ETV6-FLT3 fusion in the study patient. (A) Skin rash at presentation. (B, top) Representative histologic smears from bone marrow at diagnosis, following sorafenib therapy, and in full MRD-negative complete response after gilteritinib. (B, bottom) Skin biopsy samples showed involvement by same infiltrative process affecting bone marrow. (C) Partial karyogram showing t(12;13)(p13;q12) and FISH confirming ETV6 rearrangement in multiple sorted abnormal cell populations. (D) Schematic illustration of fusion gene product and transcript sequence of the ETV6 (NM_001987)-FLT3 (NM_004119) in-frame fusion product. Exons 1-6 of ETV6 are fused to exons 14-24 of FLT3, which include the kinase domain. Red and blue rectangles represent bidirectional RNA-sequencing reads supporting the fusion breakpoint. H&E, hematoxylin and eosin; HLH, helix-loop-helix domain; KID, kinase insert domain.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal